BCMA and TACI Immunogenic Peptides for Targeted CTL Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including surgeries, chemotherapies, and immune therapies, often yield unsatisfactory outcomes, necessitating the development of more effective therapies and prophylactic regimens for treating cancers, particularly those that target B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI).
Innovation Solution
Immunogenic peptides specific to BCMA and TACI, administered alone or in combination with immune modulators, checkpoint inhibitors, and adjuvants, to stimulate cytotoxic T cells (CTLs) and induce targeted immune responses against BCMA- and TACI-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (surgeries, chemotherapies, immune therapies) are used, then treatment coverage is broad, but therapeutic efficacy is unsatisfactory
Solution Approach 1:
The patent segments the cancer treatment approach by identifying and targeting specific antigens (BCMA and TACI) that are uniquely expressed on cancer cells. This segmentation allows for targeted peptide-based vaccines that focus immune responses on specific cancer cell populations, thereby improving therapeutic efficacy while maintaining the ability to address different cancer types expressing these antigens.
Solution Approach 2:
The invention applies local quality by designing peptides with specific amino acid sequences that bind to MHC molecules and present antigenic determinants unique to BCMA and TACI-expressing cancer cells. This localized targeting ensures that immune responses are directed specifically at cancer cells with the desired antigen expression, improving efficacy without compromising broader treatment applicability.
2Reliability
If immunogenic peptides specific to BCMA and TACI are used, then immune recognition of cancer cells is enhanced, but treatment complexity increases
Solution Approach 1:
The patent extracts the essential antigenic components by identifying specific peptide sequences from BCMA and TACI proteins that serve as immunogenic determinants. These extracted peptide sequences are then used to create simplified vaccine formulations that focus on the most critical antigenic regions, enhancing immune recognition while avoiding the complexity of using entire protein structures.
Solution Approach 2:
The invention employs parameter changes by modifying peptide sequences to optimize their binding affinity to MHC molecules and their immunogenicity. By carefully adjusting amino acid compositions and sequences, the patent achieves enhanced immune recognition efficacy while maintaining manageable treatment protocols that do not require excessive complexity.
3Reliability
If peptide sequences are modified to enhance immunogenicity, then immune response is improved, but peptide specificity may be compromised
Solution Approach 1:
The patent applies dynamics by creating multiple peptide variants with different amino acid sequences that all target the same BCMA and TACI antigens. This dynamic approach allows the immune system to encounter multiple epitopes from the same antigen, strengthening the overall immune response while maintaining specificity through the common target antigen. The invention provides flexibility in peptide selection based on individual patient needs and immune responses.
Data Source
AI summary
This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.